Ovid's research seeks to develop medicines using novel and clinically relevant endpoints to capture tangible patient benefits that emanate from addressing underlying disease pathology.

While these rare neurological disorders are each caused by distinct genetic mutations in the brain, they result in similar impairments and symptoms – seizures, developmental and learning delays, sleep disturbances, and movement and behavioral issues. Due to the similar features and symptoms expressed in these disorders, the company believes they can develop medicines with broad potential applications across a number of rare neurological diseases.